Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen?

Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen?

CLICK HERE FOR CME CREDIT

Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Stephen Ruoss, MD

Stephen Ruoss, MD

Clinical Chief, Pulmonary and Critical Care Medicine Division
Department of Medicine
Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center
Medical Director, Stanford Medical Center Transfer Center,
Stanford Univer